Hennion & Walsh Asset Management Inc. Purchases 3,673 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Hennion & Walsh Asset Management Inc. raised its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 1.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 199,525 shares of the company’s stock after buying an additional 3,673 shares during the quarter. Hennion & Walsh Asset Management Inc. owned 0.28% of Kiniksa Pharmaceuticals worth $3,947,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of KNSA. Nordea Investment Management AB boosted its position in shares of Kiniksa Pharmaceuticals by 4.4% during the 4th quarter. Nordea Investment Management AB now owns 194,883 shares of the company’s stock valued at $3,818,000 after acquiring an additional 8,257 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Kiniksa Pharmaceuticals during the third quarter worth about $4,997,000. Franklin Resources Inc. lifted its stake in Kiniksa Pharmaceuticals by 1.7% during the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock worth $1,798,000 after purchasing an additional 1,100 shares during the period. XTX Topco Ltd boosted its holdings in Kiniksa Pharmaceuticals by 62.2% during the third quarter. XTX Topco Ltd now owns 27,302 shares of the company’s stock valued at $682,000 after purchasing an additional 10,474 shares in the last quarter. Finally, Castleark Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $4,178,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock opened at $18.39 on Friday. The stock’s fifty day moving average is $20.76 and its 200-day moving average is $23.21. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15. The stock has a market capitalization of $1.33 billion, a PE ratio of -131.35 and a beta of 0.29.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. During the same quarter in the previous year, the business posted ($0.20) EPS. The company’s revenue was up 67.4% compared to the same quarter last year. As a group, analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, January 13th. The stock was sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the sale, the chief operating officer now directly owns 88,975 shares of the company’s stock, valued at approximately $1,622,904. This trade represents a 13.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the sale, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,092 shares of company stock valued at $471,609 over the last quarter. Corporate insiders own 54.57% of the company’s stock.

Analysts Set New Price Targets

KNSA has been the subject of several analyst reports. JPMorgan Chase & Co. raised their target price on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Wedbush reissued an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Monday. Finally, Evercore ISI upped their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $36.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.